January 26, 2024
Through companion diagnostics (CDx), a patient can receive individualized treatment designed to improve clinical outcomes while avoiding adverse effects. A key component of precision medicine, CDx can also lead to significant cost savings, cutting up to 60% of the total clinical trial research and development costs. The global CDx market thus has been growing rapidly and is estimated to reach USD 17.6 billion by 2027. It is crucial for companies developing CDx programs to choose a partner with the right capabilities and experience, especially with validations required for approval from regulatory bodies, such as the FDA. Our experience supporting successful CDx clinical trials globally has helped us gain deep insights into CDx development best practices.